Clinical trial
Chemoprevention of Oral Premalignant Lesions
NCT00036283 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00036283 |
|---|---|
| Title | Chemoprevention of Oral Premalignant Lesions |
| Official title | Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Precancerous Conditions |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 42 |
| Start date | Nov 1, 2000 |
| Completion | Apr 1, 2004 |
| First posted | May 9, 2002 |
| Last update posted | Sep 29, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: